X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), it is in development for the treatment of atopic dermatitis (AD) and asthma.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. As an inhibitor of IL-4Rα, CBP-201 blocks inflammatory signaling by both IL-4 and IL-13.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
Details:
CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), a validated target for the treatment of several inflammatory diseases, including AD.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Primary endpoint of IGA of 0 or 1 with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group (p < 0.001).
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
CBP-201, is a human monoclonal antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
CBP-201, discovered internally using proprietary Immune Modulation Technology Platform, is an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of several inflammatory diseases, including atopic dermatitis.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Data and analyses support the potential for a highly competitive efficacy and safety profile for CBP-201, target interleukin-4 receptor alpha that includes a differentiated Q4W dosing schedule in patients with moderate-to-severe atopic dermatitis.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2022
Details:
CBP-201 an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), has been in clinical trials for the treatment of atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
CBP-201, data show that the trial met its primary efficacy endpoint with statistically significant improvements in the percentage reduction in the Eczema Area and Severity Index .
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
Details:
The global clinical trial will assess the efficacy, safety, and pharmacokinetics (PK) profile of CBP-201, was designed to enroll 220 subjects and is being conducted at 60 sites across the US, China, Australia, and New Zealand.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2021
Details:
Connect's lead candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD) and asthma.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Renaissance Capital
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 26, 2021
Details:
CBP-201 is a potent monoclonal antibody against IL-4Rα. Data support further evaluation of CBP-201’s effects in an ongoing dose-ranging study in patients with moderate-to-severe AD.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The study conducted in ten sites in Australia and New Zealand, evaluated the efficacy and safety of CBP-201 in 31 patients with moderate-to-severe AD who have had inadequate response to topical corticosteroids and immunosuppressants.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
The company plans to use the proceeds to support the ongoing Phase 2 clinical trial for CBP-201; Phase 2 trials of CBP-307; expand the CBP-201 clinical development program into additional indications; and to support planned Phase 3 trials of CBP-201 and CBP-307.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 24, 2020
Details:
CBP-201 is a novel IL-4Rα antibody that, in a Phase 1b trial, demonstrated an efficacy profile superior to data from clinical studies of the current standard of care therapy for AD after four weeks of treatment.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Data show superior efficacy after four weeks of treatment and more rapid onset of action for CBP-201 compared with data from studies of current standard of care therapy for AD.
Lead Product(s): CBP-201
Therapeutic Area: Dermatology Product Name: CBP-201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
